Neuroimmune mechanisms of the cerebellum–brainstem network in autoimmune encephalitis and related neuroimmune disorders: antibody targets, selective vulnerability, and translational opportunities
Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 102 references
TL;DR
The cerebellum–brainstem network is used as an anatomical and clinical organizing framework rather than proposing a discrete anatomical axis or a new disease entity for AE, and a hypothesis-generating circuit framework linking immune target engagement to cerebellar output and connected brainstem manifestations is presented.
Abstract
Autoimmune encephalitis (AE) comprises clinically and immunopathologically heterogeneous central nervous system disorders whose early recognition should be syndrome-based and should not depend on antibody results alone. Cerebellar and brainstem manifestations occur in selected AE and related central nervous system neuroimmune disorders, but their frequency, anatomical specificity, and mechanisms remain incompletely defined. In this narrative Review, we use the cerebellum–brainstem network as an anatomical and clinical organizing framework rather than proposing a discrete anatomical axis or a new disease entity. In selected neuronal-surface-antibody disorders, antibodies can directly alter receptor trafficking, receptor availability, protein interactions, or synaptic transmission, whereas intracellular-antigen-associated and paraneoplastic syndromes are more often linked to cytotoxic T-cell-dominant neuronal injury. To stabilize disease scope, central AE and directly relevant central nervous system autoimmune syndromes form the core evidence base; immune-mediated cerebellar ataxias, paraneoplastic syndromes, acute disseminated encephalomyelitis, and myelin oligodendrocyte glycoprotein antibody-associated disease are included only when they provide direct infratentorial evidence; and Miller Fisher syndrome and Guillain–Barré syndrome are retained solely as peripheral anatomical comparators, whereas Bickerstaff brainstem encephalitis represents a central brainstem syndrome. We present a hypothesis-generating circuit framework linking immune target engagement to cerebellar output and connected brainstem manifestations, while explicitly marking extrapolations from non-AE models as hypotheses [H]. We also distinguish a predominantly functional pattern from an established structural-injury pattern as non-sequential research constructs rather than stages, biomarker-defined transitions, treatment windows, or clinical algorithms. Current imaging studies demonstrate that infratentorial metabolic and structural abnormalities can occur, but no reproducible cerebellum–brainstem diagnostic, prognostic, or treatment-selection signature has been prospectively validated.
Abstract Autoimmune epilepsy, once regarded as a rare and poorly understood subset of seizure disorders, has now emerged as a clinically significant and potentially reversible cause of epilepsy. Advances in neuroimmunology have substantially broadened the spectrum of neural autoantibodies implicated in epileptogenesis—particularly those directed against neuronal cell surface and synaptic proteins, such as the N-methyl-D-aspartate receptor (NMDAR), leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and glutamic acid decarboxylase 65 (GAD65). Distinct autoantibody profiles are now recognized to correlate with characteristic clinical syndromes, facilitating earlier and more targeted diagnosis. For instance, faciobrachial dystonic seizures are highly suggestive of LGI1 antibody-mediated encephalitis, while neuropsychiatric manifestations and movement disorders are typical of NMDAR antibody encephalitis, and chronic temporal lobe epilepsy frequently accompanies GAD65 autoimmunity. Early identification of these immune-mediated forms is critical, as antibody-mediated epilepsies involving cell surface antigens often respond favorably to immunotherapy, leading to substantial recovery. In contrast, epilepsies associated with intracellular antigen targets or cytotoxic T-cell–driven mechanisms, such as Rasmussen encephalitis, typically show poor therapeutic response due to irreversible neuronal injury. Some autoimmune encephalitides also occur as paraneoplastic syndromes, underscoring the importance of comprehensive oncological evaluation in affected patients. Moreover, immune dysregulation has been implicated in catastrophic epileptic conditions such as new-onset refractory status epilepticus and febrile infection-related epilepsy syndrome, further broadening the clinical spectrum of autoimmune-mediated seizures. Although seizures may arise from diverse etiologies, immune mechanisms have gained increasing recognition as an important and potentially modifiable contributor to epileptogenesis. This recognition has been formally endorsed by the International League Against Epilepsy, which classifies autoimmune epilepsy as a distinct diagnostic entity. Nevertheless, true autoimmune epilepsy, in which seizure susceptibility persists after resolution of encephalitic activity, remains relatively uncommon. In most cases, seizures associated with autoimmune encephalitis are acute and reversible with timely immunotherapy. Thus, precise terminology—differentiating acute symptomatic seizures from chronic autoimmune-associated epilepsy—is essential for appropriate management, prognostication, and research standardization.
Monika Singla, Abhishek Dixit, M. Mehndiratta· International Journal of Epi...· 0 citations
This review synthesizes advances in neuroimmunology, clinical phenotyping, diagnostics, immunomodulatory and antiseizure therapies, neuromodulation, and patient and family centered outcomes, and outlines future directions focused on biomarker-driven precision medicine, disease-modifying strategies, and interdisciplinary care models.
Alica M. Goldman, Nora Wong, A. Vezzani et al.· Epilepsy Currents· 0 citations
Autoimmune encephalitis (AE) is an increasingly recognised cause of subacute encephalopathy, behavioural change, seizures, and movement disorders in children. The recognition of antibody-mediated syndromes—principally anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis—has transformed the field, and refined diagnostic criteria now allow earlier treatment initiation. However, diagnostic delay remains common in paediatric practice and contributes to long-term neurocognitive morbidity. We review the contemporary spectrum of paediatric autoimmune encephalitis, including anti-NMDAR encephalitis, MOG antibody-associated disease overlap syndromes, and seronegative AE phenotypes, with emphasis on early recognition, diagnostic algorithms, immunotherapy, and long-term outcomes. Anti-NMDAR encephalitis is the most frequent paediatric AE worldwide, characterised by behavioural change, language regression, seizures, dyskinesias, and autonomic instability; ovarian teratoma is uncommon in prepubertal children. MOG antibody-associated disease can present with encephalopathy, particularly in younger children, often with concurrent demyelinating features. Seronegative AE poses particular diagnostic challenges. Across cohorts, diagnostic delay is associated with worse outcomes, more relapses, and persistent cognitive, behavioural, and academic difficulties. Earlier recognition through clinician education, paediatric-specific diagnostic algorithms, and rapid antibody testing pathways is essential. Long-term neurocognitive surveillance and individualised rehabilitation are critical, even in children with apparently good motor recovery. Research priorities include validation of paediatric-specific diagnostic criteria, biomarker-guided immunotherapy escalation, and population-based cohorts capturing developmental trajectories.
Human leukocyte antigen (HLA) polymorphism shapes antigen presentation and susceptibility to immune-mediated disease. In neuroimmune disorders, a central question is how HLA-dependent antigen visibility becomes disease-specific immunity and tissue injury. In this Review, we integrate genetic, molecular, cellular, and clinical evidence across multiple sclerosis (MS), neuromyelitis optica spectrum disorder, Guillain–Barré syndrome, narcolepsy, autoimmune encephalitis, and myasthenia gravis. The HLA-DR15-MS axis is the most mechanistically resolved example, linking allele-specific peptide display to autoreactive T-cell repertoires and convergent Epstein–Barr virus-related immune pathways. In other disorders, this upstream principle operates through distinct effectors, target tissues, molecular subtypes, and ancestral contexts, while causal peptide-receptor complexes often remain unresolved. We therefore separate association strength from mechanistic resolution and position glial activation and tissue injury mainly as downstream, context-dependent processes. This evidence-bounded synthesis identifies where HLA mechanisms are established, suggestive, or still inferred from association.
Shuo Liu, Siwen Yang, Jing Hu et al.· Frontiers in Immunology· 0 citations
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most common autoimmune encephalitis, primarily affecting the central nervous system (CNS) and typically presenting with neuropsychiatric symptoms. However, emerging evidence suggests that peripheral nervous system (PNS) involvement may also occur in some cases.
To investigate the clinical and neuro-electrophysiological characteristics of PNS involvement in patients with positive anti-NMDAR antibodies in cerebrospinal fluid (CSF).
We retrospectively reviewed all patients with CSF-confirmed anti-NMDAR encephalitis at the Second Affiliated Hospital of Guangzhou Medical University between 2016 and 2025. Collected data included initial symptoms and disease severity, CSF and serum test results, magnetic resonance imaging (MRI) and neuro-electrophysiological findings, primary treatment regimens, presence of coexisting autoimmune disorders, and clinical outcomes.
Among the 46 patients with anti-NMDAR encephalitis, 9 patients (19.6%) exhibited PNS involvement. The average age of onset in this subgroup with PNS involvement were significantly older than those with CNS involvement only (mean ± SD: 36.2 ± 18.9 years vs. 24.6 ± 12.4 years;
P
= 0.029). Limb weakness was significantly more frequent in the PNS involvement group (55.6% vs. 2.7%;
P
< 0.001). Electromyography (EMG) was performed in 18 patients (39.1%), of whom 10 patients (55.6%) showed abnormal findings. Among these, 1 patient exhibited active radiculopathy associated with motor neuron disease, 2 patients had isolated radiculopathy, and 1 patient presented with mixed polyneuropathy involving both motor and sensory functions. Cranial nerve involvement was observed in 2 patients (22.2%). In one case, PNS involvement was the initial symptom.
All patients received first-line immunotherapy. PNS involvement was not significantly associated with disease prognosis.
PNS involvement in anti-NMDAR encephalitis is not uncommon and most frequently manifests as acute or subacute limb weakness. Neuro- electrophysiological abnormalities predominantly involve motor conduction pathways and proximal nerve roots. This is a single-center retrospective study with a small sample size. Large-sample prospective studies are needed to further validate the findings.
Wenjie Wang, Lihui Zhu, Zhiting Li et al.· Frontiers in Immunology· 0 citations
Current evidence on advances in clinical research and immunotherapy across the major autoimmune CNS disease groups is synthesized, with a particular focus on trial designs, endpoints, and the evolution from observational cohorts to randomized controlled trials.
